DZ2333A1 - Conjugues utiles au traitement du cancer de la prostate - Google Patents

Conjugues utiles au traitement du cancer de la prostate

Info

Publication number
DZ2333A1
DZ2333A1 DZ970183A DZ970183A DZ2333A1 DZ 2333 A1 DZ2333 A1 DZ 2333A1 DZ 970183 A DZ970183 A DZ 970183A DZ 970183 A DZ970183 A DZ 970183A DZ 2333 A1 DZ2333 A1 DZ 2333A1
Authority
DZ
Algeria
Prior art keywords
treatment
prostate cancer
conjugates useful
conjugates
useful
Prior art date
Application number
DZ970183A
Other languages
English (en)
French (fr)
Inventor
Victor M Garsky
Dong-Mei Feng
Deborah Jones
Original Assignee
Merck & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co Ltd filed Critical Merck & Co Ltd
Application granted granted Critical
Publication of DZ2333A1 publication Critical patent/DZ2333A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
DZ970183A 1996-10-30 1997-10-29 Conjugues utiles au traitement du cancer de la prostate DZ2333A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DZ2333A1 true DZ2333A1 (fr) 2002-12-28

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970183A DZ2333A1 (fr) 1996-10-30 1997-10-29 Conjugues utiles au traitement du cancer de la prostate

Country Status (31)

Country Link
EP (1) EP0942754B1 (is)
JP (1) JP2000509407A (is)
KR (1) KR100508199B1 (is)
AR (1) AR008907A1 (is)
AT (1) ATE239509T1 (is)
AU (1) AU726434B2 (is)
BG (1) BG64768B1 (is)
BR (1) BR9712589A (is)
CA (1) CA2268738A1 (is)
CO (1) CO4930281A1 (is)
CZ (1) CZ155599A3 (is)
DE (1) DE69721810T2 (is)
DK (1) DK0942754T3 (is)
DZ (1) DZ2333A1 (is)
EA (1) EA002066B1 (is)
EE (1) EE03858B1 (is)
ES (1) ES2196374T3 (is)
HR (1) HRP970566A2 (is)
HU (1) HUP0000651A3 (is)
ID (1) ID21358A (is)
IL (1) IL129356A0 (is)
IS (1) IS5025A (is)
NO (1) NO992069L (is)
PE (1) PE17399A1 (is)
PL (1) PL333004A1 (is)
PT (1) PT942754E (is)
SK (1) SK57399A3 (is)
TR (1) TR199901485T2 (is)
TW (1) TW425286B (is)
WO (1) WO1998018493A2 (is)
YU (1) YU21399A (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000367A2 (en) * 1997-12-02 2000-12-31 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
WO2000003737A2 (en) * 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble drugs and methods for their production
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
PT1144011E (pt) * 1998-12-11 2010-06-16 Coulter Pharm Inc Compostos pró-fármacos e processo para a sua preparação
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
WO2001028593A2 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2003512475A (ja) * 1999-10-27 2003-04-02 メルク エンド カムパニー インコーポレーテッド 前立腺癌の治療に有用な複合体の塩形態
HUP0300590A2 (hu) * 2000-03-15 2003-07-28 Bristol-Myers Squibb Pharma Company Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
WO2008067495A2 (en) * 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
AU2010223565B2 (en) * 2009-03-09 2016-06-23 Ktb Tumorforschungsgesellschaft Mbh Prodrugs
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
ES2873846T5 (en) 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
PT942754E (pt) 2003-08-29
EA002066B1 (ru) 2001-12-24
NO992069D0 (no) 1999-04-29
IS5025A (is) 1999-04-13
CO4930281A1 (es) 2000-06-27
KR20000052970A (ko) 2000-08-25
ATE239509T1 (de) 2003-05-15
EE03858B1 (et) 2002-10-15
BG103436A (en) 2000-04-28
EP0942754B1 (en) 2003-05-07
AU5149798A (en) 1998-05-22
NO992069L (no) 1999-06-30
YU21399A (sh) 2000-03-21
AU726434B2 (en) 2000-11-09
IL129356A0 (en) 2000-02-17
EA199900428A1 (ru) 2000-02-28
WO1998018493A2 (en) 1998-05-07
HK1024876A1 (en) 2000-10-27
HUP0000651A2 (hu) 2000-06-28
DE69721810D1 (de) 2003-06-12
HRP970566A2 (en) 1998-08-31
ID21358A (id) 1999-05-27
TW425286B (en) 2001-03-11
KR100508199B1 (ko) 2005-08-17
CZ155599A3 (cs) 1999-10-13
WO1998018493A3 (en) 1998-07-23
EP0942754A2 (en) 1999-09-22
ES2196374T3 (es) 2003-12-16
TR199901485T2 (xx) 1999-08-23
CA2268738A1 (en) 1998-05-07
SK57399A3 (en) 2000-01-18
DK0942754T3 (da) 2003-08-04
EE9900179A (et) 1999-12-15
HUP0000651A3 (en) 2001-12-28
PL333004A1 (en) 1999-11-08
PE17399A1 (es) 1999-02-20
AR008907A1 (es) 2000-02-23
BG64768B1 (bg) 2006-03-31
DE69721810T2 (de) 2004-03-11
JP2000509407A (ja) 2000-07-25
BR9712589A (pt) 1999-10-26

Similar Documents

Publication Publication Date Title
DZ2333A1 (fr) Conjugues utiles au traitement du cancer de la prostate
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
PT1028954E (pt) Imidazoles substituidos uteis no tratamento de doencas inflamatorias
FI970990A7 (fi) Syövän toteaminen ja hoito
FI20031516A7 (fi) Indolokarbatsolijohdannaisten käyttö eturauhasen patologisten tilojen hoidossa
FI972484L (fi) Karsinooman hoito
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
DE59701536D1 (de) Fibrillationsarmer formkörper
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
NO984906D0 (no) Vannbehandling
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
GB9626309D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
GB9718160D0 (en) Conjugates useful in the treatment of prostate cancer
GB9815855D0 (en) Conjugates useful in the treatment of prostate cancer
GB9810183D0 (en) Conjugates useful in the treatment of prostate cancer
GB9804399D0 (en) Conjugates useful in the treatment of prostate cancer
KR970034786U (ko) 차체의 배수 글로멧
KR980000678U (ko) 반신 좌욕기
KR970060742U (ko) 질삽입구
FI970767A0 (fi) Reaaliaikainen maksumenetelmä